enGene (NASDAQ:ENGNW) Stock Price Up 12.6% – Still a Buy?

Shares of enGene Holdings Inc. (NASDAQ:ENGNWGet Free Report) shot up 12.6% during mid-day trading on Wednesday . The company traded as high as $0.23 and last traded at $0.22. 15,330 shares traded hands during mid-day trading, a decline of 7% from the average daily volume of 16,570 shares. The stock had previously closed at $0.1953.

enGene Trading Up 2.3%

The business’s fifty day simple moving average is $0.30 and its 200 day simple moving average is $1.19.

About enGene

(Get Free Report)

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Further Reading

Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.